We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 0.69% | 220.00 | 218.00 | 219.50 | 223.00 | 212.50 | 219.00 | 275,208 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.67 | 211.03M |
TIDMOXB
RNS Number : 7123B
Oxford Biomedica PLC
10 June 2019
PDMR Dealings / Market Share sale
Oxford, UK - 10 June 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 June 2019, that Dr. Jason Slingsby, Chief Business Officer of the Group, exercised 12,014 options at 274.7p each and sold all of the resulting shares at 760p. Following this transaction he holds 91,822 options and no shares in the Company.
The issued share capital of the Group is 76,738,168 ordinary 50p shares.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Jason Slingsby ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Business Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford BioMedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial ISIN: GB00BDFBVT43 instrument Identification code ----------------------------- ----------------------------------- b) Nature of the Exercise of options transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP2.747 12,014 ---------- ----------------------------- ----------------------------------- e) Aggregated information 12,014 * Aggregate volume GBP2.747 GBP33,002.46 * Price * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2019-06-07 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- ----------------------------------- 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Jason Slingsby ----------------------------- ----------------------------------- 2. Reason for the notification ------------------------------------------------------------------ a) Position/status Chief Business Officer ----------------------------- ----------------------------------- b) Initial notification/ Initial Notification amendment ----------------------------- ----------------------------------- 3. Details of the Issuer ------------------------------------------------------------------ a) Name Oxford BioMedica plc ----------------------------- ----------------------------------- b) LEI code 213800S1GVQNXQ15K851 ----------------------------- ----------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------ a) Description of Ordinary Shares of 50 pence each the financial ISIN: GB00BDFBVT43 instrument Identification code ----------------------------- ----------------------------------- b) Nature of the Disposal transaction ----------------------------- ----------------------------------- c) Currency GBP - British pound ----------------------------- ----------------------------------- d) Price(s) and volumes(s) Price(s) Volume(s) GBP7.60 12,014 ---------- ----------------------------- ----------------------------------- e) Aggregated information 12,014 * Aggregate volume GBP7.60 GBP91,306.40 * Price * Aggregated total ----------------------------- ----------------------------------- f) Date of the transaction 2019-06-07 ----------------------------- ----------------------------------- g) Place of the transaction London Stock Exchange, Main Market (XLON) ----------------------------- -----------------------------------
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Stuart Paynter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHBXGDLXXBBGCG
(END) Dow Jones Newswires
June 10, 2019 09:34 ET (13:34 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions